Vaidyane Ayurved LaboratoriesNSE:MADHAVBAUG 84 Gross Margin % is 81.33% as of Mar. 2026, which is 12% above its 10-year median of 72.37. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 84/100 and a GF Value™ of ₹228.10 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 938 Drug Manufacturers companies, Vaidyane Ayurved Laboratories ranks better than 94.14% on this metric.
NSE:MADHAVBAUG's Gross Margin % is ranked better than 94.14% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:MADHAVBAUG: 82.29
Vaidyane Ayurved Laboratories had a gross margin of 81.33% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vaidyane Ayurved Laboratories had a gross margin of 81.33% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vaidyane Ayurved Laboratories Gross Margin % Related Terms
Vaidyane Ayurved Laboratories Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MADHAVBAUG vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Gross Margin % of 81.33% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 12% above median its historical median of 72.37. Over the past decade, Vaidyane Ayurved Laboratories' Gross Margin % has ranged from 67.88 to 82.29. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #55 out of 938 companies in the Drug Manufacturers industry, placing it in the top 5.9%.
Is Vaidyane Ayurved Laboratories' Gross Margin % too high?
Vaidyane Ayurved Laboratories' current Gross Margin % of 81.33% is 12% above median its 10-year median of 72.37. Over the past 10 years, this metric has ranged from a low of 67.88 to a high of 82.29. The Drug Manufacturers industry median Gross Margin % is 48.54. Vaidyane Ayurved Laboratories' value of 81.33% is 67.6% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #55 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #55 out of 938 companies for Gross Margin %. This places Vaidyane Ayurved Laboratories in the top 6% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Vaidyane Ayurved Laboratories' value of 81.33% is 67.6% above this benchmark. Historically, Vaidyane Ayurved Laboratories' own Gross Margin % has ranged from 67.88 to 82.29 over the past decade. While the company's 10-year median is 72.37 vs. the industry median of 48.54, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Gross Margin % of 81.33% is 67.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Gross Margin % is 81.33%, which is 12% above median its own 10-year median of 72.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.10, compared to a current price of ₹182.00 — trading 20.2% below its estimated fair value. The current Gross Margin % is 81.33%, which is 12% above median its 10-year median of 72.37 and 67.6% above the Drug Manufacturers industry median of 48.54. Vaidyane Ayurved Laboratories' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Gross Margin % is 81.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹182.00 is trading 20.2% below its estimated GF Value™ of ₹228.10.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
Gross Margin %: 81.33% (12% above median its 10-year median of 72.37)
GF Value™: ₹228.10 vs. price of ₹182.00 (20.2% below fair value)
Industry Position: 67.6% above the Drug Manufacturers median (#55 of 938)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
84GF Score
Get the complete analysis for NSE:MADHAVBAUG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
